Konstantinos Leventakos

机构：Mayo Clinic, North Central Cancer Treatment Group, WinnMed, Mayo Clinic in Arizona, Mayo Clinic in Florida · ORCID：0000-0001-9784-8603

发表论文 280 篇 · 总被引 4138 次 · h-index 27

代表论文

• Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial (2026 · Journal of Thoracic Oncology · 被引 6)
• Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support (2025 · Supportive Care in Cancer · 被引 1)
• 844 Immune cell profile changes in patients treated with tarlatamab for extensive-stage small cell lung cancer in real world practice (2025 · Regular and Young Investigator Award Abstracts · 被引 1)
• Oncologic and physiologic predictors of mortality after intensive care unit admission in patients with lung cancer (2025 · Annals of the American Thoracic Society · 被引 1)
• Safety and Efficacy of Sequential Chemoimmunotherapy Followed by Concurrent Chemoradiation in Unresectable Stage III NSCLC (2025 · JTO Clinical and Research Reports · 被引 1)
• The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer (2026 · Clinical Cancer Research)